加替沙星眼用凝胶
Search documents
兴齐眼药(300573)披露公司产品继续纳入医保目录,12月08日股价上涨0.16%
Sou Hu Cai Jing· 2025-12-08 09:59
Core Viewpoint - The company Xingqi Eye Pharmaceutical (300573) has maintained a strong position in the national medical insurance drug list, which is expected to positively impact its long-term business performance [1]. Group 1: Stock Performance - As of December 8, 2025, Xingqi Eye Pharmaceutical's stock closed at 73.09 yuan, up 0.16% from the previous trading day [1]. - The stock opened at 73.19 yuan, reached a high of 74.18 yuan, and a low of 72.97 yuan, with a trading volume of 4.49 billion yuan and a turnover rate of 3.23% [1]. Group 2: National Medical Insurance Drug List - The National Healthcare Security Administration has included 39 products from Xingqi Eye Pharmaceutical in the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List, with 8 in Category A and 31 in Category B, and no products being removed [1]. - Key products such as Cyclosporine Eye Drops (II), Compound Electrolyte Eye Wash, and Sodium Hyaluronate Eye Drops continue to be included, while the restriction on the use of Gatifloxacin Eye Gel has been lifted [1]. - The new drug list will take effect on January 1, 2026, and is expected to have a long-term positive impact on the company's operating performance, although there is no significant short-term impact [1].
兴齐眼药:39个产品继续被纳入2025年国家医保目录
Zheng Quan Shi Bao Wang· 2025-12-07 08:31
Core Viewpoint - The company Xingqi Eye Medicine (300573) announced that 39 of its products will continue to be included in the 2025 National Medical Insurance Catalog, with no products being removed from the catalog [1] Group 1 - The company has 39 products included in the 2025 National Medical Insurance Catalog, consisting of 8 Class A and 31 Class B products [1] - Specific products such as Cyclosporine Eye Drops (II), Compound Electrolyte Eye Irrigation Solution, and Sodium Hyaluronate Eye Drops will continue to be covered [1] - The statement regarding the use of Gatifloxacin Eye Gel as a "second-line medication" has been removed from the catalog notes [1] Group 2 - The inclusion status of the company's other products in the 2025 National Medical Insurance Catalog remains unchanged from the 2024 catalog [1]